Denosumab as a potential treatment alternative for patients suffering from diffuse sclerosing osteomyelitis of the mandible—a rapid communication

Diffuse sclerosing osteomyelitis (DSO) is a rare disease of the jaw bone. Its treatment is challenging. Different medical and surgical treatment protocols have been proposed; however, none of these treatment protocols produce reliable results. Recently, ibandronate administration has been attempted as a treatment alternative in acute cases of DSO. Due to the similar antiresorptive effect, we sought to explore the application of the human monoclonal antibody to the receptor activator of nuclear factor kappaB ligand (RANKL), denosumab, in the treatment of DSO.

from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2gaEwik
via IFTTT